Acer Therapeutics Inc

Acer Therapeutics — Opexa Therapeutics — Investor Presentation (September 2016)

24 slides from Acer Therapeutics's investor presentation, Sep 12, 2016

  1. Slide 1: Precision Immunotherapy

    Precision Immunotherapy®

  2. Slide 2: Forward-Looking Statements

    eB OPEXA Tt Forward-Looking Statements All statements in this presentation other than those of historical fact, including statements regarding our preclinical and clinical development plans for Tcelna® and OPX-212, our research and other development programs, our ability to undertake certain activit

  3. Slide 3: Opexa Highlights (Nasdaq: OPXA)

    Opexa Highlights (Nasdaq: OPXA) Opexa: A leading force in personalized therapies for autoimmune diseases Advanced, proprietary platform: Lead asset in Phase 2b development Lead indication: Secondary Progressive Multiple Sclerosis (SPMS) Next inflection point: In 1-2 months with top-line Phase 2b dat

  4. Slide 4: Opexa's T-Cell Immunotherapy Platform

    ‘ep OPEXA Opexa’s T-Cell Immunotherapy Platform Combatting autoimmune disease * Restoring the function of an individual’s faulty immune system ° Modulating the body’s immune cells (T-cells) to enable the person to fight the disease itself ° Making individually precise therapies by harnessing cells f

  5. Slide 5: Near Term Possible Value Generation: 1-2 months

    ‘ep OPEXA Near Term Possible Value Generation: 1-2 months The Abili-T trial ° Phase 2b top-line data in SPMS expected in early Q4 2016 ° 180 patient trial, 35 centers in U.S. and Canada ¢ Final patient visit has now been completed ° End points: 1) Brain atrophy and 2) disease progression ° FDA Fast

  6. Slide 6: Significant Market Potential: Secondary Progressive MS

    Significant Market Potential: Secondary Progressive MS * Secondary Progressive MS market potential in North America could exceed $7 billion (for all SPM S therapies) Reece * Roughly 150,000 SPMS patients in North America $7 Billion (est.)} * Only one drug approved for SPMS in U.S. (none in EU or Asi

  7. Slide 7: Additional Near Term Possible Value Generation

    ‘ep OPEXA Additional Near Term Possible Value Generation Potential Partner Merck Serono signed option and license agreement in 2013 Following evaluation of Phase 2 data, they could exercise their option, which would trigger: — Milestone payment to Opexa (up to $25 million to proceed to Phase 3) — Me

  8. Slide 8: Opexa's Novel Approach; Priming the Immune System

    OPEXA’S NOVEL APPROACH; PRIMING THE IMMUNE SYSTEM

  9. Slide 9: Root Cause of MS: Activated T-cells Degrade Myelin

    @e OPEXA THERAPEUTICS Root Cause of MS: Activated T-cells Degrade Myelin and Damage Myelin Producing Cells In MS patients, the faulty immune system is not able to prevent the attack of a small sub- population of myelin reactive T-cells (MRTC) MRTCs cross the blood brain barrier, enter the brain, and

  10. Slide 10: Tcelna Could Address the Root Cause of MS

    @e OPEXA THERAPEUTICS Tcelna Could Address the Root Cause of MS by Preventing Demyelination and Enabling Remyelination * Therapeutic dose of Tcelna (attenuated T-cell clones) is injected subcutaneously + This triggers an immune response specifically targeting circulating MRTC + Immune cells, includi

  11. Slide 11: Tcelna for Multiple Sclerosis

    TCELNA® FOR MULTIPLE SCLEROSIS

  12. Slide 12: Clinical Evidence for Tcelna MoA

    OPEXA THE Clinical Evidence for Tcelna MoA T-cell technology demonstrated a significant reduction in reactive T-cells (52 week study results of MS) Reduction in MRTC Week 0 0% =p” -10% -20% -30% -40% -50% ~60% -70% -80% -90% -100% MRTC: Myelin Reactive T-cells Week 13 Week 21 Week 28 Week 52 + Resul

  13. Slide 13: SPMS Patient Data: Previous Studies

    ‘ep OPEXA THERAPE SPMS Patient Data: Previous Studies Tcelna stabilizes disease in SPMS Patients at 2 years 80% of patients showed no further disease progression by EDSS at 2 years Stabilization vs. Historical Progression o 100% 71 s 3) 2 = 80% EI 80% Ze u Stable oo 9, 25 60% 2 § @ Progressed f= KE

  14. Slide 14: Results of Phase 2b TERMS study in RRMS

    ‘eo OPEXA THERAPEUTICS Results of Phase 2b TERMS study in RRMS Reversal of disability in prospective analysis in more active patients Sub-population of patients (n=50) with more progressed/active disease profile (baseline ARR >1) Annualized Relapse Rate (ARR) at week 52 Change in Disability (EDSS) a

  15. Slide 15: ImmPath: Opexa's Proprietary T-Cell Immunotherapy Platform

    IMMPATH®: OPEXA’S PROPRIETARY T-CELL IMMUNOTHERAPY PLATFORM

  16. Slide 16: ImmPath: Harnessing the Power of the Patient's Own Immune System

    ‘ep OPEXA ImmPath®: Harnessing the Power of the Patient’s Own Immune System to Restore Tolerance Manufacturing and QC Dispensation Procurement 35 Days Day —— \ &S \ 4 AN + >t + -Gf — =, | G : Antigen-sourced Expansion of Attenuation Formulation & Administration seed material T-cells cryopreservation

  17. Slide 17: Leveraging the T-Cell Platform: OPX-212 for NMO

    LEVERAGING THE T-CELL PLATFORM: OPX-212 FOR NEUROMYELITIS OPTICA (NMO)

  18. Slide 18: NMO: A Rare Disease of the Central Nervous System

    ‘ee OPEXA NMO: A Rare Disease of the Central Nervous System * Neuromyelitis optica (NMO) is a rare or orphan autoimmune disease * Immune system cells and antibodies mistakenly attack and destroy myelin cells in the optic nerves and the spinal cord * Individuals with NMO develop optic neuritis, which

  19. Slide 19: Key Operational Milestones Achieved For NMO Program

    ‘ee OPEXA THERAPE Key Operational Milestones Achieved For NMO Program FDA feedback + Conducted pre-IND meeting to discuss pre-clinical and clinical program to support OPX-212 development in NUO Preclinical animal study + — Results show statistically significant dose dependent reduction of AQP4 react

  20. Slide 20: Key Financial Data

    KEY FINANCIAL DATA

  21. Slide 21: Financials

    iy OPEXA Financials Cash and Cash Equivalents (MM) as of June 30, 2016 ~$7.8 Shares outstanding (MM) ~7.0 Shares issuable for Warrants (MM) outstanding as of June 30, 2016 ~3.6 Shares issuable for Stock Options (MM) outstanding as of June 30, 2016 ~0.62) Debt None (1) Weighted average exercise price

  22. Slide 22: Summary and Overview

    ow OPEXA SUMMARY AND OVERVIEW

  23. Slide 23: Expected Milestones

    @e OPEXA THERAPEUTICS Expected Milestones Q2 ‘16 Q3 °16 ay Q4 °16 Qi 17 . Potential Top-line Merck option data exercise and expected *— milestone payment to Opexa ($25MM)

  24. Slide 24: Opexa Therapeutics: A Leader in Developing T-Cell Immunotherapies

    . ‘ep OPEXA Opexa Therapeutics: A Leader in Developing T-Cell Immunotherapies PIPELINE * Tcelna®: Phase 2b for secondary progressive multiple sclerosis (SPMS), limited competition, $7BN overall market potential + Top line results expected for Abili-T Phase 2b SPMS trial in early Q4 2016 + OPX-212: P

Opexa Therapeutics — Investor Presentation (September 2016) on 6ix